Shire to sell oncology business to Servier for $2.4bn

Shire to sell oncology business to Servier for $2.4bn

Shire to sell oncology business to Servier for $2.4bn

Shire has agreed to sell its cancer drugs business to French drugmaker Servier for $2.4bn, even as it prepared for a possible takeover offer from Takeda.

Don't expect the sale of the oncology business to spark a cash infusion into Shire's R&D. Takeda's interest in Shire (Hamburg: 3979575.HM - news) was made public only at the end of last month.

The UK Takeover Panel gave the Japanese firm a deadline of April 25 to announce a firm intention to bid or walk away. The market value of Shire is about $47 billion. A pursuit of Shire would be one of the biggest attempts by a Japanese company to buy a Western rival.

Galaxy Note 9 Codename, iPhone X-Like Notch Revealed In Fresh Leaks
Samsung's mobile business head DJ Koh has told media that the Galaxy Note 9 would come with an upgraded Bixby 2.0 AI assistant. Earlier, Ming Chi Kuo, the analyst at KGI Securities , stated that the Note 9 would come with a design similar to the Note 8.

Shire CEO Dr Flemming Ørnskov said: "This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio".

The proceeds from the transaction, which is expected to close in this or next quarter, would "increase optionality". Launched in 19 countries, Lonsurf generated €62 million ($76.8 million) in revenue during 2016-2017, according to a Servier announcement that did not furnish revenues for Pixuvri.

Shire's oncology business includes products such as Oncaspar (pegaspargase), part of a multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to Onivyde (irinotecan pegylated liposomal formulation), part of a multi-agent treatment for metastatic pancreatic cancer after gemcitabine-based therapy, and Calaspargase Pegol (Cal-PEG), which is now under review by the U.S. Food and Drug Administration (FDA) for the treatment of ALL and early stage immuno-oncology pipeline collaborations.

Eggs sold in Virginia stores and restaurants being recalled due to salmonella
Further, officials said that eggs emerging from this farm were likely connected to 22 reported cases of salmonella infections . Over 200 million eggs are part of the voluntary recall because they might be contaminated with salmonella .

"We see the possible strategic fit given the company's focus therapeutic areas of oncology, gastrointestinal and neuroscience, with Shire bolstering the latter two franchises", Jefferies analyst Peter Welford wrote in reference to Takeda in an April 16 note.

If Takeda does make an official bid for Shire, this sale might make it slightly more affordable.

Its oncology business had sales of $262 million a year ago, putting the divestment on a respectable revenue multiple of 9.2 times. Meanwhile, privately held Servier says adding Shire's cancer drugs will give it a commercial presence in the USA while also strengthening its portfolio in the parts of the world where the France-based company is already established.

Excessive automation at Tesla was a mistake: Elon Musk
Institutions purchase large blocks of a company's outstanding shares and can exert considerable influence upon its management. Volume is an important indicator in technical analysis as it is used to measure the relative worth of a market move.

Meanwhile, Servier group president Olivier Laureau said the acquisition will enable the company to "meet its strategic ambitions to become a global key player in oncology", in particular by helping it establish a direct commercial presence in the US.

Latest News